Tumor metabolism and blood flow as assessed by positron emission tomography varies by tumor subtype in locally advanced breast cancer.
OBJECTIVE
Dynamic positron emission tomography (PET) imaging can identify patterns of breast cancer metabolism and perfusion in patients receiving neoadjuvant chemotherapy (NC) that are predictive of response. This analysis examines tumor metabolism and perfusion by tumor subtype.


METHODS
Tumor subtype was defined by immunohistochemistry in 71 patients with locally advanced breast cancer undergoing NC. Subtype was defined as luminal [estrogen receptor (ER)/progesterone receptor (PR) positive], triple negative [TN; ER/PR negative, human epidermal growth factor receptor 2 (HER2) negative], and HER2 (ER/PR negative, HER2 overexpressing). Metabolic rate (MRFDG) and blood flow (BF) were calculated from PET imaging before NC. Pathologic complete response (pCR) to NC was classified as pCR versus other.


RESULTS
Twenty-five (35%) of 71 patients had TN tumors; 6 (8%) were HER2 and 40 (56%) were luminal. MRFDG for TN tumors was on average 67% greater than for luminal tumors (95% confidence interval, 9-156%) and average MRFDG/BF ratio was 53% greater in TN compared with luminal tumors (95% confidence interval, 9-114%; P<0.05 for both). Average BF levels did not differ by subtype (P=0.73). Most luminal tumors showed relatively low MRFDG and BF (and did not achieve pCR); high MRFDG was generally matched with high BF in luminal tumors and predicted pCR. This was not true in TN tumors.


CONCLUSIONS
The relationship between breast tumor metabolism and perfusion differed by subtype. The high MRFDG/BF ratio that predicts poor response to NC was more common in TN tumors. Metabolism and perfusion measures may identify subsets of tumors susceptible and resistant to NC and may help direct targeted therapy.
Specht
Jennifer M
JM
Medical Oncology and Nuclear Medicine, Department of Medicine, University of Washington, Seattle, Washington 98109, USA. jspecht@uw.edu
Kurland
Brenda F
BF
Montgomery
Susan K
SK
Dunnwald
Lisa K
LK
Doot
Robert K
RK
Gralow
Julie R
JR
Ellis
Georgina K
GK
Linden
Hannah M
HM
Livingston
Robert B
RB
Allison
Kimberly H
KH
Schubert
Erin K
EK
Mankoff
David A
DA
D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000098:blood supply* / Q000000981:diagnostic imaging* / Q000378:metabolism*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D049268:Positron-Emission Tomography; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000096:biosynthesis; D011960:Receptors, Estrogen / Q000096:biosynthesis; D011980:Receptors, Progesterone / Q000096:biosynthesis
D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
J Nucl Med. 2002 Apr;43(4):500-9
11937594
Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23
12829800
Nature. 2000 Aug 17;406(6797):747-52
10963602
Radiol Clin North Am. 2005 Jan;43(1):121-34
15693652
J Clin Oncol. 2009 Mar 10;27(8):1160-7
19204204
Cancer Res. 1986 May;46(5):2578-81
3697997
Clin Cancer Res. 2009 Sep 1;15(17):5294-6
19706819
J Clin Oncol. 2011 Mar 10;29(8):1014-21
21220618
Clin Cancer Res. 2005 Aug 15;11(16):5678-85
16115903
J Natl Cancer Inst. 1958 Dec;21(6):1039-63
13611531
Ann Biomed Eng. 2000 Aug;28(8):922-9
11144676
Acad Radiol. 2008 Oct;15(10):1246-54
18790395
Clin Cancer Res. 2009 Sep 1;15(17):5511-7
19706808
J Clin Oncol. 2008 Mar 10;26(8):1275-81
18250347
Arch Surg. 1989 Jan;124(1):21-5
2910244
J Nucl Med. 1986 Feb;27(2):235-8
3712040
Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2196-201
16452162
BMC Cancer. 2007 Nov 01;7:203
17976237
J Nucl Med. 2004 Nov;45(11):1829-37
15534051
Clin Cancer Res. 2007 Apr 15;13(8):2329-34
17438091
J Appl Physiol (1985). 2004 Jul;97(1):404-15
15220323
Cancer Imaging. 2008 Mar 25;8:81-6
18390391
J Nucl Med. 2003 Nov;44(11):1806-14
14602864
Mol Imaging Biol. 2008 Nov-Dec;10(6):356-63
18709508
Nat Clin Pract Oncol. 2008 Mar;5(3):149-59
18212769
Lancet Oncol. 2007 Mar;8(3):235-44
17329194
Cancer. 1997 Nov 1;80(9):1803-4
9351551
Semin Nucl Med. 2009 Jan;39(1):36-51
19038599
Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74
11553815
J Clin Oncol. 2008 Sep 20;26(27):4449-57
18626006
Cancer. 2008 Mar 1;112(5):995-1000
18098228
Cold Spring Harb Symp Quant Biol. 2005;70:357-62
16869772
Oncology (Williston Park). 2005 Apr;19(4 Suppl 3):7-16
15934498
J Clin Oncol. 2008 Feb 10;26(5):786-90
18258987